Richtlijn CVRM feb2013 - KNMP

Leest 2006
Leon 1998
Leest LATM van, Verschuren WMM, Leefstijl- en risicoindicatoren voor hart- en vaatziekten in de
Nederlandse bevolking: prevalenties en trends. In: Jager-Geurts MH, Peters RJG, van Dis SJ, Bots ML,
Hart- en vaatziekten in Nederland 2006, cijfers over ziekte en sterfte. Den Haag: Nederlandse
Hartstsichting 2006.
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three
antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study
Investigators. N Eng J Med 1998; 339: 1665-71.
Lestra 2005 Iestra JA, Kromhout D, Van der Schouw YT, Grobbee DE, Boshuizen HC, Van Staveren WA.
Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronairy
artery disease patients, a systematic literature review. Circulation 2005; 112: 924-934.
Lewis 2001 Lewis RL, Calver J, Kun Zhu, Flicker L, Prince RL, Calcium supplementation and the risks of
atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4,5 year
follow-up. Journal of Bone and Mineral Research 2001; 26: 35-41.
Li 2003
Li 2012
Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by
C-reactieve protein and lipopolysaccharide. Coron Artery Dis 2003; 14: 329-334.
Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium
supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in
the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study
(EPIC-Heidelberg). Heart 2012; 98 (12): 920-925.
Lindgren 2004 Lindgren A, Husted S, Staaf G, et al. Dipyridamole and headache. A pilot study of intitial dose
titration. J Neur Scie 2004; 223: 179-84.
Lindholm 2002
Lindholm 2005
Loke 2011
Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity
and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.
Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of
primary hypertension A meta-analysis. Lancet 2005; 366: 1545-1553.
Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolismsystematic
review and adjusted indirect comparison. J Clin Pharm Ther 2011; 36 (1): 111-124.
Loomba 2010 Loomba RS, Arora R. Prevention of cardiovascular disease utilizing fibrates: a pooled
meta-analysis. American Journal of Therapeutics.2010;17(6):e182-e188.
Lorgeril 2010 Lorgeril de M, Salen P, Abramson J; Dodin S; Hamazaki T, Kostucki W, et al. Cholesterol
Lowering, cardiovascular diseases, and the Rosuvastatin-JUPITER Controversy. A critical
repraisal. Arch Intern Med 2010; 170 (12): 1032-1036.
Maas 2011a Maas AHEM, vd Schouw YT, Regitz-Zagorsek V, Swahn E, Appelman YE et al, Red alert for
women’s heart: the urgent need for more research and knowledge on cardiovascular disease
women. Eur Heart Jr 2011;32: 1362-1368.
in
Maas 2011b Maas AHEM, Lagro-Jansen T en de Boer MJ, Acuut coronair syndroom bij vrouwen onder de
60 jaar. NTvG 2011 (155): 1697-1701.
Machado 2007 Machado MM, Bajcar J, Guzzo GC en Einarson TR. Sensitivity of Patient Outcomes to
Pharmacist Interventions. Part II: Systemetic Review and Meta-analysis in Hypertension
Management. Ann. of Pharmacotherapy 2007; (41): 1770-1781.
Machado 2008 Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to
pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia
management. Ann Pharmacother. 2008; 42(9): 1195-207.
Maillette 2011 Maillette de Buy Wenniger, L. Betrouwbare bloeddruk in 30 minuten. Ned Tijschr Geneeskd
2011; 155: C901.
93
CONCEPT